These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38882208)

  • 41. Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion.
    Li P; Faraone JN; Hsu CC; Chamblee M; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Xu K; Liu SL
    bioRxiv; 2024 May; ():. PubMed ID: 38826376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.
    Sohail MS; Ahmed SF; Quadeer AA; McKay MR
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe.
    Kostaki EG; Mossialos E; Tseti I; Sfikakis PP; Paraskevis D
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680171
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antigenic Characterization of Circulating and Emerging SARS-CoV-2 Variants in the U.S. throughout the Delta to Omicron Waves.
    Di H; Pusch EA; Jones J; Kovacs NA; Hassell N; Sheth M; Lynn KS; Keller MW; Wilson MM; Keong LM; Cui D; Park SH; Chau R; Lacek KA; Liddell JD; Kirby MK; Yang G; Johnson M; Thor S; Zanders N; Feng C; Surie D; DeCuir J; Lester SN; Atherton L; Hicks H; Tamin A; Harcourt JL; Coughlin MM; Self WH; Rhoads JP; Gibbs KW; Hager DN; Shapiro NI; Exline MC; Lauring AS; Rambo-Martin B; Paden CR; Kondor RJ; Lee JS; Barnes JR; Thornburg NJ; Zhou B; Wentworth DE; Davis CT
    Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793756
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa.
    Sun K; Tempia S; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; Carrim M; Martinson NA; Kahn K; Lebina L; du Toit JD; Mkhencele T; Viboud C; Cohen C;
    medRxiv; 2022 Aug; ():. PubMed ID: 36032973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.
    Zaballa ME; Perez-Saez J; de Mestral C; Pullen N; Lamour J; Turelli P; Raclot C; Baysson H; Pennacchio F; Villers J; Duc J; Richard V; Dumont R; Semaani C; Loizeau AJ; Graindorge C; Lorthe E; Balavoine JF; Pittet D; Schibler M; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe KM; Kaiser L; Trono D; Stringhini S; Guessous I;
    Lancet Reg Health Eur; 2023 Jan; 24():100547. PubMed ID: 36474728
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5.
    Tseng HF; Ackerson BK; Bruxvoort KJ; Sy LS; Tubert JE; Lee GS; Ku JH; Florea A; Luo Y; Qiu S; Choi SK; Takhar HS; Aragones M; Paila YD; Chavers S; Talarico CA; Qian L
    Nat Commun; 2023 Jan; 14(1):189. PubMed ID: 36635284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB.
    Ding Y; Fan F; Xu X; Zhao G; Zhang X; Zhao H; Wang L; Wang B; Gao XM
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112691
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization.
    Morris CP; Eldesouki RE; Sachithanandham J; Fall A; Norton JM; Abdullah O; Gallagher N; Li M; Pekosz A; Klein EY; Mostafa HH
    Clin Infect Dis; 2023 Apr; 76(7):1276-1284. PubMed ID: 36366857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
    Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
    Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
    Xiang T; Wang J; Zheng X
    Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of multiplex allele-specific RT-qPCR assays for differentiation of SARS-CoV-2 Omicron subvariants.
    Li J; Cheng R; Bian Z; Niu J; Xia J; Mao G; Liu H; Wu C; Hao C
    Appl Microbiol Biotechnol; 2024 Dec; 108(1):35. PubMed ID: 38183475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of mutations defining SARS-CoV-2 Omicron subvariants BA.2.12.1 and BA.4/5 on Spike function and neutralization.
    Pastorio C; Noettger S; Nchioua R; Zech F; Sparrer KMJ; Kirchhoff F
    iScience; 2023 Nov; 26(11):108299. PubMed ID: 38026181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.
    Wang L; Møhlenberg M; Wang P; Zhou H
    Cytokine Growth Factor Rev; 2023 Apr; 70():13-25. PubMed ID: 36948931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.
    Wang Q; Guo Y; Iketani S; Nair MS; Li Z; Mohri H; Wang M; Yu J; Bowen AD; Chang JY; Shah JG; Nguyen N; Chen Z; Meyers K; Yin MT; Sobieszczyk ME; Sheng Z; Huang Y; Liu L; Ho DD
    Nature; 2022 Aug; 608(7923):603-608. PubMed ID: 35790190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
    Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants.
    Li Y; Shen Y; Zhang Y; Yan R
    Viruses; 2023 Jun; 15(6):. PubMed ID: 37376697
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A long-term cohort study: the immune evasion and decreasing neutralization dominated the SARS-CoV-2 breakthrough infection.
    Liu Q; Jin M; Mei F; Fan H; Gu M; Zhang Y; Qian S; Tan X; Ji L; Zhang Z; Chen G; Yan H; Chen Y; Lan K; Geng Q; Cai K; Zhou L
    Front Cell Infect Microbiol; 2024; 14():1381877. PubMed ID: 38572316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.